Eli Lilly and Company has announced a definitive agreement to acquire clinical-stage biopharmaceutical firm AtaiBeckley in a transaction valued at up to $3.8 billion. The acquisition aims to significantly expand Lilly’s neuroscience pipeline by integrating advanced neuroplastogen therapies designed to treat complex and treatment-resistant mental health conditions. Key Regulatory Proposals The financial terms of the agreement include an initial $2.8 billion upfront cash paymen

The European Commission has issued marketing authorization for once-daily oral semaglutide 25 mg tablets, marketed under the Wegovy brand, for the management of obesity and weight-associated comorbidities in adults. This regulatory milestone marks the introduction of the first GLP-1 receptor agonist in oral form for weight management within the European Union, extending the drug’s existing presence in the United States, the United Kingdom, the United Arab Emirates, and Bahra